So it looks like psoriasis can be treated with growth hormone inhibitors.
Psoriasis and human growth hormone: aetiology and therapy.
http://www.ncbi.nlm.nih.gov/pubmed/6115617
Treatment of psoriasis with somatostatin.
http://www.ncbi.nlm.nih.gov/pubmed/6131648
Growth Hormone, Somatostatin and Psoriasis
http://www.karger.com/Article/PDF/247890
Treatment of severe psoriasis with intravenous somatostatin
http://www.tandfonline.com/doi/abs/10.3109/09546638909086677?journalCode=ijdt20
Treatment of psoriasis with bromocriptin.
Maybe Chad should have tried a GH-inhibitor rather than a GH-releasing peptide?
Psoriasis and human growth hormone: aetiology and therapy.
First report on nine patients suffering from psoriasis who were treated with somatostatin or bromocriptin or both. These are inhibitors of HGH. The therapeutical effect on skin lesions and psoriatic alterations to joints is described.
http://www.ncbi.nlm.nih.gov/pubmed/6115617
Treatment of psoriasis with somatostatin.
In 22 of 26 patients suffering from psoriasis the drip infusion therapy with Somatostatin, an inhibitor of the human growth hormone (HGH), leads to complete or partial remission of skin lesions. Fast reduction of joint pains in arthropathic psoriasis could be observed in four of four patients. The repeated measurement of HGH blood level showed a decrease of HGH in five cases following the Somatostatin therapy combined with the clinical remission.
http://www.ncbi.nlm.nih.gov/pubmed/6131648
Growth Hormone, Somatostatin and Psoriasis
http://www.karger.com/Article/PDF/247890
Treatment of severe psoriasis with intravenous somatostatin
Previous uncontrolled studies have reported the beneficial effects of somatostatin in the treatment of psoriasis. This manuscript reports a double-blind, placebo-controlled study of intravenous somatostatin vs placebo in 21 patients with chronic plaque psoriasis vulgaris. Seven of nine patients receiving somatostatin were found to improve on somatostatin compared to one of eleven patients receiving placebo. It would seem justified to perform further clinical studies on the effects of somatostatin in chronic severe psoriasis.
http://www.tandfonline.com/doi/abs/10.3109/09546638909086677?journalCode=ijdt20
Treatment of psoriasis with bromocriptin.
Sixty patients suffering from psoriasis of all clinical forms have been treated with an increased dosage of Bromocriptin. The age of the patients ranged from 20 to 72 years. Patients with contraindications for Bromocriptin were excluded from the test. In 80% a remission or reduction ofpsoriasis lesions was noticed. Side effects in the form of nausea, dizziness and vomiting occurred in 15%, but decreased in the course of Bromocriptin therapy.
Maybe Chad should have tried a GH-inhibitor rather than a GH-releasing peptide?